Free Trial
NASDAQ:RANI

Rani Therapeutics Q3 2023 Earnings Report

Rani Therapeutics logo
$1.06 -0.03 (-2.31%)
As of 10:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rani Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Rani Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rani Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, November 8, 2023
Conference Call Time
4:00PM ET

Earnings Documents

Rani Therapeutics Earnings Headlines

Rani Therapeutics (RANI) Expected to Announce Earnings on Monday
REVEALED: Elon’s Secret Master Plan “AGENDA X”
REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street
RANI: 2024 Financial Results
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

View Rani Therapeutics Profile

More Earnings Resources from MarketBeat